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1. Introduction
   In year 2014, the most serious Ebola outbreak in Africa and 
becomes the present global threat. Thousands of Africans get 
infected and there are many death cases. The drug searching for 
combating the present outbreak of Ebola virus infection is the 
urgent activity at present[1]. World Health Organization declares 
and calls for international collaboration for fighting the big 
outbreak of Ebola virus in Africa[2,3]. Finding a new effective 
drug at present must base on the molecular analysis of the 
pathogenic virus. The in-depth analysis of the viral protein to find 
the binding site, active pocket is needed[4]. This can be done by a 
complex crystallography study. With the advent of bioinformatics 
technology at present, it is possible to further manipulate on the 
crystallography data of the focused viral protein. The druggability 
within the identified active pocket can be further analyzed.
2. Materials and methods
   The authors firstly searched for the crystallography data of 
envelope glycoprotein GP2 from Ebola virus. The public available 
data, PubMed, was used as the basic search tool. The derived “Core 
Structure Of GP2 From Ebola Virus [Envelope Glycoprotein]” 
from Ebola virus- Mayinga, Zaire, 1976 was used as the primary 
template for further analysis of protein active pocket and 
druggability. To analyze for protein active pocket and druggability, 
the standard bioinformatics technology was used. DoGSiteScorer 
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was the main tool for analysis[5]. 
3. Results
   According to the search, the standard referenced Protein Data 
Bank crystal structure of the envelope glycoprotein GP2 from 
Ebola virus could be derived and used for further manipulation. 
According to the analysis, there are 7 identified active pockets 
within the studied molecules with druggability ranging from 0.25 
to 0.73 (Table 1). 
Table 1 
Identified active pocket and corresponding druggability (listed by volume 
from the most to the least).
Identified 
pockets
Area 
(Angstrom3)
Volume 
(Angstrom2)
Drug score
1 986.23 345.66 0.67
2 385.20 309.57 0.73
3 456.43 294.27 0.59
4 351.14 175.36 0.39
5 237.39 173.25 0.37
6 100.72 144.51 0.41
7 353.67 128.96 0.25
4. Discussion
   The success for control of the present outbreak of Ebola virus 
2014 might be depended on two main thing: drug and vaccine[1]. 
To search for new drugs, we need the complete knowledge on the 
viral protein structure and the interrelation to possible new drugs. 
Identification on the active pocket, which can be the binding site 
to newly developed drug is needed[6]. Here, the authors studied the 
important molecule, envelope glycoprotein GP2 from Ebola virus. 
The technique use in this study is the standard technique used in 
many recent studies[7,8].
   In fact, envelope glycoprotein GP2 from Ebola virus is the well-
known target for trial for control of the Ebola virus. This protein 
plays an important role in cell invasion of virus[9], hence, if there 
is any new drug attacking this protein, it will be a good drug for 
fighting the virus, preventing it from cellular entry[10]. In this 
work, the authors use the referencing bioinformatics method for 
assessment of active pocket and druggability within envelope 
glycoprotein GP2[11]. It is successful to identify 7 pockets with can 
be selectable for further development of the new drug for targeting 
of drug binding to those active pocket. Selection of the active 
pocket with large size and high drug score to be the first focused 
target is suggested.
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